NEO Neogenomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEO

Price (delayed)

$14.87

Market cap

$1.9B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$2.18B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The company's EPS rose by 35% YoY and by 6% QoQ
The net income has grown by 33% YoY and by 4.2% from the previous quarter
The equity is down by 5% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://neogenomics.com/
Peers: RDNT DGX LH ENZ

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
127.71M
Market cap
$1.9B
Enterprise value
$2.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.05
Price to sales (P/S)
3.07
EV/EBIT
N/A
EV/EBITDA
1,640.53
EV/Sales
3.56
Earnings
Revenue
$610.66M
EBIT
-$81M
EBITDA
$1.33M
Free cash flow
-$39.59M
Per share
EPS
-$0.66
Free cash flow per share
-$0.31
Book value per share
$7.24
Revenue per share
$4.84
TBVPS
$5.97
Balance sheet
Total assets
$1.64B
Total liabilities
$716.93M
Debt
$608.18M
Equity
$923.41M
Working capital
$497.19M
Liquidity
Debt to equity
0.66
Current ratio
7.48
Quick ratio
6.85
Net debt/EBITDA
208.35
Margins
EBITDA margin
0.2%
Gross margin
41.8%
Net margin
-13.8%
Operating margin
-16.9%
Efficiency
Return on assets
-5%
Return on equity
-8.9%
Return on invested capital
-8.3%
Return on capital employed
-5.2%
Return on sales
-13.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-1.39%
1 week
2.48%
1 month
11.97%
1 year
-14.79%
YTD
-8.1%
QTD
7.21%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$610.66M
Gross profit
$255.26M
Operating income
-$103.23M
Net income
-$84.23M
Gross margin
41.8%
Net margin
-13.8%
NEO's net margin is up by 42% YoY and by 7% QoQ
Neogenomics's operating margin has increased by 36% YoY and by 7% from the previous quarter
The net income has grown by 33% YoY and by 4.2% from the previous quarter
The company's operating income rose by 27% YoY and by 4.2% QoQ

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
NEO P/E details
P/E
N/A
P/B
2.05
P/S
3.07
EV/EBIT
N/A
EV/EBITDA
1,640.53
EV/Sales
3.56
The company's EPS rose by 35% YoY and by 6% QoQ
The price to book (P/B) is 44% less than the 5-year quarterly average of 3.7 but 4% more than the last 4 quarters average of 2.0
The equity is down by 5% year-on-year
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 6.4 and 6% lower than the last 4 quarters average of 3.3
The revenue rose by 15% YoY and by 3.2% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales rose by 47% YoY and by 13% QoQ
NEO's ROIC is up by 33% year-on-year and by 9% since the previous quarter
The return on assets rose by 31% year-on-year and by 3.8% since the previous quarter
The return on equity has increased by 29% year-on-year and by 3.3% since the previous quarter

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 129% greater than the total liabilities
NEO's current ratio is up by 21% from the previous quarter and by 11% YoY
The quick ratio has grown by 21% from the previous quarter and by 10% YoY
NEO's debt is 34% lower than its equity
The equity is down by 5% year-on-year
The debt to equity rose by 4.8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.